New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 21, 2014
09:13 EDTKOOLThermogenesis, TotipotentRX report significant Phase Ib trial results
ThermoGenesis and TotipotentRX announce their co-sponsored Phase Ib clinical trial safety and efficacy results treating no-option patients suffering from critical limb ischemia with Totipotent's Critical Limb Ischemia Rapid Stem cell Therapy, or CLIRST, treatment. The trial achieved both its primary safety and secondary efficacy endpoints at 12 months, achieving statistical significance in five key areas including, major amputation free survival rates, both resting and walking pain reduction, improved walking distance, open wound healing and vasculogenesis in the treated leg. Furthermore, there were no serious adverse events determined to be related to the therapy.
News For KOOL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 26, 2015
20:44 EDTKOOLMarcum to hold a conference
Subscribe for More Information
May 20, 2015
08:18 EDTKOOLCesca Therapeutics receives IEC/IRB approval to initiate AMI study
Subscribe for More Information
May 15, 2015
16:40 EDTKOOLCesca Therapeutics to delay filing Form 10-Q
The registrant is unable to file its Quarterly Report on Form 10-Q for the quarter ended March 31, within the prescribed time period. As reported in the company’s Form 8-K dated May 12, the former independent registered public accounting firm resigned. The company needs more time to engage a successor independent registered public accounting firm and allow them time to review the management prepared Form 10-Q. No assurance can be given that the company will be able to file its quarterly report within the additional time prescribed by Rule 12b-25.
10:01 EDTKOOLOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:10 EDTKOOLCesca Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use